Virtual program

APLAR 2020 program is now available!

The virtual program has been designed with you in mind! Scheduled within the GMT +7 timezone and across a week to ensure that you can attend as many sessions as you want. 

Please note that this program is subject to change. 


Pre-Congress program

Friday 23 October
1400-1700Pre-Congress workshop

Biomechanics & Movement Workshop with BJC Health


Brought to you by

Main program

Saturday 24 October
1000 – 1130Plenary session 1: Management of rheumatic diseases during the COVID-19 pandemic

Speakers
COVID-19 in rheumatology practice in Japan
Tsutomu Takeuchi, Keio University School of Medicine, Japan

TBA

TBA
1130 – 1245Morning symposium 1

“Beyond remission” based on patients’ subjective experiences for improved RA control


Morning symposium 2

How to diagnose Spondyloarthritis in daily practice ~peripheral manifestation and EAM~


Morning symposium 3

New evidence on the JAK inhibitor and its clinical implications for rheumatoid arthritis


Morning symposium 4
Brought to you by Brought to you by Brought to you by
1245 – 1315Break
1315 – 1445
Lunch symposium 1

Prospects for JAK inhibitors in the treatment of rheumatoid arthritis


Lunch symposium 2

Basic and Clinical of Rheumatology


Brought to you by
Brought to you by
1500 – 1640SpA – 1: New advances in Axial
Spondyloarthritis
SLE – 1: Progress and perspectives on SLE in the APLAR regionImaging: Imaging in rheumatic diseases – where do we standTreating children with rheumatic diseases in Asia Pacific: The Great Divide
Chairpersons:
Mitsumasa Kishimoto
Katy Leung
Nazrul Islam
Chairpersons:
Sandra Navarra
Yoshiya Tanaka
Chairpersons:
Chi-Chen Chang
Ved Chaturvedi
Chairpersons:
Masaki Mori
Surjit Singh
Outcome of Juvenile spondyloarthropathy in adulthood
Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, India
Patient education as vital to improving outcomes
Laniyati Hamijoyo, University of Padjadjaran, Indonesia
Ultrasound and its clinical use in rheumatoid arthritis
Kei Ikeda, Chiba University Hospital, Japan
Asia-Pacific Pediatric Rheumatology: Where Do We Stand
Sumaira Farman, National Hospital & Medical Center; Al-Aleem Medical College; Fatima Jinnah Medical University, Pakistan
Improving Access to Care in Resource Challenged Settings: Lessons from the Paediatric Task Force Global MSK Health
Helen Foster, Newcastle University, United Kingdom
Treat-to-Target in SpA, how far are we going?
James Wei, Chung Shan Medical University Hospital, Taiwan
Progress and Perspectives on SLE in the APLAR region
Evan Vista, St. Luke’s Medical Center and College of Medicine, Philippines
Ultrasound in large vessel vasculitis
Kuo-Lung Lai, Taichung Veterans General Hospital, Taiwan
JIA: Geographic variability in treatment and long-term outcomes of JIA
Soamarat Vilaiyuk, Mahidol University, Thailand
When and how to use, or not to use MRI in SpA”
Ashish Jacob Mathew, Christian Medical College, India
Interim report of the APLAR consensus statements on the management of SLE
Chi Chiu Mok, Tuen Mun Hospital, Hong Kong
MRI in Rheumatoid Arthritis
Mami Tamai, Nagasaki University, Japan
Macrophage Activation Syndrome: Analysis of various Cytokines
Masaki Shimizu, Tokyo Medcial And Dental University, Japan
Novel assessment tool for bony damage in spondyloarthritis
Lai-shan Tam, The Chinese University of Hong Kong, Hong Kong
Ultrasound and its clinical use in spondyloarthropathy
Lee Ka Wing Gavin
Hong Kong
Autoinflammatory disorders: Spectrum seen in Asia Pacific
Sulaiman Al-Mayouf, King Faisal Specialist Hospital & Research Center, Saudi Arabia
Updates on the Asia Pacific Lupus Collaboration (APLC) cohort
Eric Morand, Australia
Vasculitis: Childhood onset Takayasu arteritis: an update
Satish Kumar, Christian Medical College, India
Panel Q&APanel Q&APanel Q&APanel Q&A
1640 – 1740Abstract session: IgG4-RD, AOSD/sJIA, Kawasaki diseaseAbstract session: SLE and APL syndrome 1Abstract session: IIM, SSc, SjSAbstract session: COVID-19 and CTD
Increased Human Neutrophil Lipocalin and its Clinical Relevance in Adult-Onset Still’s Disease
Ji Li, Peking University International Hospital, China
Platelet Indices Could Be Simple, Reliable Predictors of Thrombotic Events in Patients with Antiphospholipid Syndrome
Yu Shi, Peking Union Medical College, China
Clinical and swallowing outcomes in patients with dermatomyositis and polymyositis with dysphagia using the Food Intake LEVEL Scale
Shin-ichiro Ohmura, Seirei Hamamatsu General Hospital, Japan
Rheumatic diseases on COVID-19 era
Selma Abdellaoui, Beni Messous Hospital, Algeria
Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes
Eduardo Martín-Nares, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico
Prevalence of celiac disease in patients with systemic lupus erythematosus
Zahra Soltani, Tehran University of Medical Sciences, Iran
Immunomodulatory Therapy: a New Strategy for Dermatomyositis /Polymyositis
Shengxiao Zhang, The Second Hospital of Shanxi Medical University, China
Prevalence of emotional disorder and sleep quality in patients with systemic lupus erythematosus during COVID-19 epidemic: a cross-sectional study
Jing Zhu, Sichuan Provincial People’s Hospital, China
Abnormality of peripheral lymphocyte subsets in patients with Bechet’s disease and their restorations after receiving new immunomodulatory therapy
Shengxiao Zhang, The Second Hospital of Shanxi Medical University, China
SLE Disease Activity Score (SLE-DAS) is a comparable disease activity measure to SLEDAI-2K
Masanori Kono, University of Tokyo Hospital, Japan
Characteristics And Outcomes Of Overlap Myositis: A Comparative Multigroup Study In Adults And Children with Idiopathic Inflammatory Myopathies (IIM)
Naveen R, Sanjay Gandhi Post Graduate Institute Of Medical Sciences, India
Factors associated with use of telemedicine for follow-up of lupus nepthritis in the COVID-19 outbreak
Ho So, The Chinese University of Hong Kong, Hong Kong
Application Of Preliminary PRINTO Classification Criteria For SJIA In An Indian Cohort
Devang Pandya, Dev Children’s Hospital, India
Development of a genetic risk score for Filipino patients with systemic lupus erythematosus
Michael Tee, University of The Philippines, Philippines
Prognosis and Treatments of Patients with Myositis-associated Severe Interstitial Lung Disease: A Descriptive Study using National Inpatient Database in Japan
Hiroki Furuya, Department of Allergy And Clinical Immunology, Japan
Spectrum Of Systemic Inflammatory Syndrome In Children During COVID 19 Pandemic In India
Devang Pandya, Dev Children’s Hospital, India
Long-term outcome of 21 cases of giant coronary aneurysm after Kawasaki disease – Our 40 years’ experience
Tomomi Sato, Shiga University of Medical Science, Japan
The Association between Serum Leptin Levels, Body Mass Index, and Disease Activity in Women with Systemic Lupus Erythematosus
Nittayawadee Aeamsaard, Phramongkutklao Hospital and College of Medicine, Thailand
Nailfold Capillary Changes in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis
Tomohiro Sugimoto, Hiroshima University Hospital, Japan
Reactive arthritis after COVID-19 infection
Keisuke Ono, Kyorin University School of Medicine, Japan
Immunophenotypic analysis of peripheral blood mononuclear cells in IgG4-Related Disease
Aya Nishiwaki, The University of Tokyo, Japan
Joint Q&AIs Rituximab an Adequate Glucocorticoid-Sparing Agent in Idiopathic Inflammatory Myopathies?
Serdal Ugurlu, Istanbul University- Cerrahpasa, Turkey
A Healthy Dose of Skepticism: Eosinophilic Granulomatosis with Polyangiitis Initially Presenting as Possible COVID-19
Vincent Anthony Tang, University Of The Philippines – Philippine General Hospital, Philippines
TBAJoint Q&AAssessing the Impact on Heath Seeking Behavior During COVID-19 Outbreak in a Group of Rheumatology Patients from Sri Lanka
Sunith Atukorale, Ministry of Health, Sri Lanka
Joint Q&AJoint Q&A
1740 – 1840Evening symposium 1

Management of RA in 2020: is remission achievable and where do JAKs fit?


Evening symposium 2

Treat-to-target in SLE: addressing short- and long-term treatment goals


Evening symposium 3

ILD in Focus: Time to prioritize the lung in CTDs
Evening symposium 4

Perspectives around the accumulated evidence for IL-6 in autoimmune disease
Brought to you by Brought to you by Brought to you by Brought to you by
Sunday 25 October
1000 – 1130Plenary session 2: Past, present and future of rheumatology

Speakers:
Rheumatology: A Crystal Gaze? – a future perspective
Syed Haq, BSM Medical University, Bangladesh

TBA

Title TBA
Ian McInnes, University of Glasgow, United Kingdom
1130 – 1245Morning symposium 5

Treatment of Rheumatoid Arthritis: Past and Future

Morning symposium 6

To continue, taper or discontinue biologics – Implications on RA treatment outcomes

Morning symposium 7Morning symposium 8
Brought to you by Brought to you by
1245 – 1315Break
1315 – 1445
Lunch symposium 3
New insights for clinical practice in Spondyloarthritis, SpA

Brought to you by
Lunch symposium 4

Innovative therapeutic alternatives for Rheumatoid Arthritis, and Spondylarthritis: Individualising the treatment approach


Brought to you by
1500 – 1640Vasculitis: Merge of basic and clinical researches of vasculitisSLE – 2: SLE clinicalGenetics: recent progress in genetics of rheumatic diseasesSpA – 2: Updates in PsA
Chairpersons:
Debashish Danda
Xinping Tian
Masayoshi Harigai
Chairpersons:
Yoshiya Tanaka
Chairpersons:
Michael Tee
Zhanghou Li
Chairpersons:
Atimichi Morita
James Wei
TBAManagement of systemic lupus erythematosus (SLE) during and beyond the COVID-19 pandemic
Sandra V. Navarra, University of Santo Tomas, Philippines
GWAS, eQTL and epigenome of rheumatic diseases
Kazuhiko Yamamoto, RIKEN Center for Integrative Medical Sciences, Japan
Differential diagnosis of Psoriatic arthritis in daily practice
Mitsumasa Kishimoto, Kyorin University School of Medicine, Japan
TBA
Genetic analysis of Takayasu arteritis
Ruchika Goel, Christian Medical College, India
Risk assessment and prevention of cardiovascular co-morbidities in psoriatic arthritis
Lai-Shan Tam, The Chinese University of Hong Kong, Hong Kong
TBAContinuing challenges in lupus nephritis
Daniel TM Chan, University of Hong Kong, Hong Kong
Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population
Jianping Guo, Peking University People’s Hospital, China
Panel Q&A
TBASpecial issues on pregnancy and lactation
Aisha Lateef, Woodlands Health Campus, Singapore
Genetics of Kawasaki Disease: where are we in circa 2020
Surjit Singh, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education And Research, Chandigarh, India
Biomarker for PsA – myth or reality
Katy Leung, Singapore General Hospital, Duke-nus Medical School, Singapore
TBA
TBAGenetic risk score
Sarah Reid
TBA
Panel Q&APanel Q&APanel Q&A
1640 – 1740Abstract session: IIM, SSc, SjSAbstract session: SLE and APL syndrome 2Abstract session: OA and Crystal induced arthritisAbstract session: SpA, AS-1
Clinical Responses to Low-dose Interleukin-2 in Idiopathic Inflammatory Myopathies
Miao Miao, Peking University People’s Hospital, China
Leukocyte immunoglobulin-like receptor A3 (LILRA3) promotes lupus-like disease severity
Yundi Tang, Peking University People’s Hospital, China
The numeral changes of peripheral lymphocyte subsets in 238 patients with GOUT and their correlation analysis with disease activity
Lijun Zhao, The Second Hospital of Shanxi Medical University, China
TBA
Prediction of myocardial abnormalities in systemic sclerosis, assessed in cardiac magnetic resonance imaging, by using artificial neural networks models
Masaki Haraoka, St. Marianna University School of Medicine, Japan
Should ophthalmologic evaluation be done as a screening test for new onset lupus patients with no eye complaint?
Seyedeh Tahereh Faezi, Tehran University of Medical Sciences, Iran
Subtype Genome-Wide Meta-Analyses of Clinically-Defined Gout Revealed Multiple Subtype-Specific Gout Loci and Enrichment of Selection Pressure on ABCG2 and ALDH2
Yusuke Kawamura, National Defense Medical College, Japan
Efficacy and Safety of Brodalumab, Anti-IL-17 Receptor A Monoclonal Antibody, for Axial Spondyloarthritis, A 68-Week Result of Phase 3 Study
Tae-Hwan Kim, Hanyang University Medical Center, Democratic Republic of Korea
Clinical analysis of dermatomyositis / polymyositis / cancer-associated myositis and related research on peripheral blood CD4 + T lymphocyte subsets
Pan-di Zhang, The Second Hospital of Shanxi Medical University, China
TBASystematic Review and Meta-Analysis of the Prevalence of Neuropathic-Like Pain and Pain Sensitisation in People With Knee and Hip Osteoarthritis
Luigi Zolio, Alfred Health, Australia
Improvements in Patient-Reported Outcomes in AS Patients Treated With Golimumab: Sub-Analysis of Asian Patients Enrolled in Phase III Clinical Trials
Wen-Chan Tsai, Kaohsiung Medical University, Taiwan
Diagnostic Accuracy of Salivary Free Light Chain and Immunoglobulin Assays in Primary Sjögren’s Syndrome
Pulukool Sandhya, St Stephens Hospital Delhi, India
Voclosporin Has Demonstrated Efficacy in Asian Patients With Lupus Nephritis
Tatsuya Atsumi, Hokkaido University, Japan
A Randomised Placebo-controlled Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-synovitis of Knee Osteoarthritis (CurKOA trial)
Benny Samuel Eathakkattu Antony, University of Tasmania, Australia
Abnormality of peripheral lymphocyte subsets in patients with ankylosing spondylitis and restoration after receiving immunoregulatory combination therapies
Shengxiao Zhang, The Second Hospital of Shanxi Medical University, China
The Artificial Intelligence for the Prediction of Focal Score of Labial Salivary Gland Biopsy in the Diagnosis of Sjogren Syndrome
Nobooru Kitamura, Nihon University School of Medicine, Japan
Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: a Distinct Disease Subset from Young-onset Lupus Nephritis
Kazuoto Hiramoto, Keio University School of Medicine, Japan
The Trajectory of Exercise Adherence Over Time and the Effect of Theory-lead Intervention for Knee Osteoarthritis in Elderly
Limin Wang, Peking University, China
Comorbidity Profiles among patients with Axial Spondyloarthritis
Fariz Yahya
Effects of Nintedanib in Asian Patients with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD): Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana, Nippon Medical School, Japan
Thrombotic risk assessment in patient with systemic lupus erythematosus: validation of the adjusted-Global Antiphospholipid Syndrome Score (aGAPSS) in Thai patients
Wanitcha Chanloung, Chiang Mai University, Thailand
The Prevalence and Incidence of Symptom Knee Osteoarthritis in the Middle-aged and Elderly: a National Survey from China
Limin Wang, Peking University, China
Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from C-axSpAnd
Philip Robinson, University of Queensland, Australia
Joint Q&ASerological Evolution in Patients with Positive Antiphospholipid Antibodies-A Retrospective Study of Chinese Cohort
Lanlan Ji, Peking University First Hospital, China
Prevalence and Clinical Features of Early-onset Osteoarthritis in a Large Scale Cross-sectional Study
Jiajing Peng, Peking University People’s Hospital, China
Imbalance of Th17/Treg In Cardiovascular Diseases of Patients With Ankylosing Spondylitis
Tingting Ding, The Second Hospital of Shanxi Medical University, China
Joint Q&AJoint Q&AJoint Q&A
1740 – 1840Evening symposium 5

Addressing Unmet Needs in RA and PsA: The Right Drug for the Right Patient


Evening symposium 6

The role of interleukin-6 in rheumatoid arthritis



Evening symposium 7

Denosumab, anti-RANKL antibody, for the treatment of joint destruction in RA. − From DRIVE & DESIRABLE studies


Evening symposium 8



Brought to you by
Brought to you by
Brought to you by

Post-Congress program

Monday 26 October
1445 – 1615Update on challenges in osteoporosis managementSynovial cell biologyAbstract session: Pathogenesis, Etiology of RAAbstract session
Chairpersons:
Lau Tang Ching
Session information pendingTBAPulmonary involvement during rheumatoid arthritis
Selma Abdellaoui, Beni Messous Hospital, Algeria
Rheumatoid Arthritis associated osteoporosis and fractures- the Taiwan experience
Tien Tsai Cheng, Chang Gung Memorial Hospital, Taiwan
Ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings
Asami Abe, Japan
Anti-drug antibodies (ADA) against anti-CD22 monoclonal antibody SM03 in Chinese patients with Rheumatoid Arthritis
Xiaofeng Zeng, Peking Union Medical College Hospital, China
TBA
TBARisk of Malignancy with non-TNFi biologic or Tofacitinib therapy in Rheumatoid Arthritis: A Meta-Analysis of Observational Studies
Wenhui Xie, Peking University First Hospital, China
Development and validation of clinical predication model for patient-reported pain among rheumatoid arthritis patients
Biyu Shen, Affiliated Hospital 2 of Nantong University, China
The clinical features of peripheral lymphocyte subsets in RA patients and effects of combined immunomodulatory therapy on these cells
Shengxiao Zhang, The Second Hospital of Shanxi Medical University, China
Investigation of comorbidities affecting disease activity in rheumatoid arthritis: a register-based study
Takanori Miura, Kakunodate General Hospital, Japan
Aberrant Expression of TLR2 Enhanced CD4+ T Cell Activation and Fatty Acid β Oxidation in Rheumatoid Arthritis
Ziran Bai, Dalian Medical University, China
Characteristics of difficult-to-treat rheumatoid arthritis
Satoshi Takanashi, Keio University School of Medicine, Japan
TBARA: what we’ve learned from arthroplasty
Susan M Goodman, United States
Risk of tuberculosis in patients with rheumatoid arthritis: data from a centralized electronic database in Hong Kong
Ho Yin Chung, The University of Hong Kong, Hong Kong
Clinical characteristics of 75 patients who developed new tuberculosis in NinJa-registration of Japanese rheumatoid arthritis (RA) patient for 16-years
Yasuhiko Yoshinaga, Kurashiki Medical Center, Japan
The Risk of Developing Herpes Zoster Differs among Molecular-Targeted Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis
Takumi Muramatsu, Kitasato University School of medicine, Japan
High titer of rheumatoid factor as a critical determinant of difficult-to-treat rheumatoid arthritis: the KURAMA cohort
Ryu Watanabe, Kyoto University Graduate School of Medicine, Japan
TBAExome sequencing of Chinese anti-cyclic-citrullinated-peptide-positive rheumatoid arthritis patients
Khai Pang Leong, Tan Tock Seng Hospital, Singapore
Segmentation of Tendon for Rheumatoid Arthritis using Deep Learning in Ultrasonography
Haruyuki Watanabe, Gunma Prefectural College of Health Sciences, Japan
Utility of Measuring Immunogenicity to Novel Subcutaneous CT-P13 in Active RA Patients: 1-Year Results from a Randomized Controlled Pivotal Trial
Dae Hyun Yoo, Korean College of Rheumatology, South Korea
Development of algorithm for classification of patients into polymyalgia rheumatica and elderly onset rheumatoid arthritis using musculoskeletal ultrasonography
Kana Higashitani, National Hospital Organization Yokohama Medical Center, Japan
Panel Q&ATitle TBA
Gary Firestein
A pooled real-world long-term persistence rate of tumor necrosis factor-alpha inhibitors in rheumatic diseases: a nationwide, population-based retrospective cohort study
James Wei, Chung Shan Medical University Hospital, Taiwan
Predictors of Flare in Rheumatoid Arthritis Patients with Persistent Clinical Remission/Low Disease Activity: Data from the TARAC Cohort
Srisakul Jiemjit, Phramongkutklao Hospital and College of Medicine, Thailand
Joint Q&ADo We Need Criteria for Elderly-Onset Rheumatoid Arthritis?
Chokan Baimukhamedov, Shymkent Medical Center of Joint Diseases, Kazakhstan
Joint Q&A
1615 – 1630Break
1630 – 1800
Industry symposium
Industry symposium
1800 – 1830Poster exhibition / viewing
Tuesday 27 October
1445 – 1615Remission of RA in the
APLAR region
Crystal: Trends and practices of gout management in the Asia Pacific regionAbstract session: Basic researchAbstract session: Clinical practice and patient care
Chairpersons:
Zhanguo Li
Tsutomu Takeuchi
Chairpersons:
Paulo Lorenzo
Temy Mok
M3 muscarinic acetylcholine receptor (M3R) reactive Th17 cells in patients with primary Sjögren’s syndrome
Saori Abe, University of Tsukuba, Japan
Contribution of ultrasound to the diagnosis of the carpal tunnel syndrom
Selma Abdellaoui, Beni Messous Hospital, Algeria
Trend of remission and difficult to treat RA in a single center of Japan
Yuko Kaneko, Keio University School of Medicine, Japan
Current guidelines for the management crystal-induced (Gout) arthritis in the Asia-Pacific
Ratih Manuaba, Indonesian Rheumatism Association, Indonesia
Expanding regulatory T cells: a new strategy and therapy for rheumatic patients characterized by abnormalities of peripheral lymphocyte subsets
Jia-Qian Zhang, The Second Hospital of Shanxi Medical University, China
Could CD14+/16+ monocyte population be used as a predictor of chronic pain post total knee replacement, adjusting for subclinical fibromyalgia?
Sam Shan, Northern Health, Australia
Management of RA in India
Ramya Janardana, St John’s National Academy of Health and Allied Sciences, India
TBAAttitudes of Australians with Inflammatory Arthritis to Biologic Therapy and Biosimilars
Alannah Quinlivan, The Queen Elizabeth Hospital, Australia
Remission status of RA in APLAR countries by RA-SIG survey
Ru Li
China
Establishment of iPSc and differentiated endothelial cells of PAH associated with systemic sclerosis ; functional and molecular analysis
Yuki Kudo, Hokkaido University, Japan
Global, regional, and national burden of low back pain, 1990-2019: a systematic analysis for Global Burden of Disease Study 2019
Dongze Wu, The Third Affiliated Hospital of Sun Yat-Sen University, China
Molecular remission for further understanding of drug response in RA
Tsutomu Takeuchi, Keio University School of Medicine, Japan
Gout treatment in Chronic Kidney Diseases
Worawit Louthrenoo, Chiang Mai University, Thailand
N6-methyladenosine-modified Circ_0088194 promotes migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes through miR-766-3p/MMP2 axis
Yujie Cai, Southern Medical University, China
First Ever Single Center Study Revealing Spectrum Of Rheumatic Diseases In 114 Children From An Indian State Of Gujarat
Devang Pandya, Dev Children’s Hospital, India
New remission criteria to achieve better outcome of RA
Daniel Aletaha
Austria
Activation of Toll-like Receptor Signaling Pathway in Patients with Primary Sjögren’s Syndrome Associated Thrombocytopenia Revealed by B-Lymphocyte High-Throughput Sequencing
Shuo Zhang, Peking Union Medical College Hospital, China
Effects of Nintedanib on Patient-Reported Outcomes in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Sub-Analysis of INBUILD
Masataka Kuwana, Nippon Medical School, Japan
TBAClinical course of juvenile-onset hyperuricemia complicated by Down’s syndrome: Close correlation with thyroid dysfunction and high obesity
Toshiyuki Kitoh, Aichi Gakuin University, Japan
TBALeptin Promotes the Function of Dendritic Cells via Glycolysis
Ziran Bai, Dalian Medical University, China
Prevalence of Computer-Related Musculoskeletal Discomfort among International Islamic University Malaysia (IIUM) Female Students
Zaitunnatakh Zamli, International Islamic University Malaysia, Malaysia
CTLA4 signaling down-regulates Fcγ receptor I expression in circulating monocytes: A potential mechanism of action for RA
Ryosuke Fukue, Nippon Medical School of Rheumatology, Japan
Hydroxychloroquine in Patients with Rheumatic Disease: Analysis of Safety in a Single Centre Cohort
Avreena Bhullar, Hospital Selayang, Malaysia
Panel Q&AMetabolic Changes Induced by Anti-Malondialdehyde/acetaldehyde Antibodies Promote Osteoclast Development
Koji Sakuraba, National Hospiral Organization Kyushu Medical Center, Japan
Reasons for Discontinuation of Biological Drugs Among Patients with Inflammatory Arthritis in the United Arab Emirates
Sakina Asghar, American School of Dubai, United Arab Emirates
TGFβ1 Suppresses Human RANKL-Induced Osteoclast Differentiation via Downregulation of NFATc1 and RANK Expression
Tadahiro Tokunaga, Hiroshima University Hospital, Japan
Joint Q&A
Joint Q&A
1615 – 1630Break
1630 – 1800
Industry symposium
Industry symposium
1800 – 1830Poster exhibition / viewing
Wednesday 28 October
1435 – 1615Epidemiology COPCORDScleroderma / MyositisAbstract session: Treatment of RAAbstract session: PsA
Chairperson:
Arvind Chopra
Chairpersons:
Andrea Low
Padmanabha Shenoy
So Ho
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis of FINCH 3
Tatsuya Atsumi, Hokkaido University, Japan
Abnormality of peripheral lymphocytes subsets in psoriatic arthritis patients and restoration after receiving new immunoregulatory combination therapies: a cross-sectional study
Shengxiao Zhang, The Second Hospital of Shanxi Medical University, China
The COPCORD Asia Pacific Epidemiology- A Learning For the Future
Prof Atiqul Haq Sayed, BSM Medical University, Bangladesh
TBATBATBA
Making sense of the existent Phase 1 data
Nazrul Islam
Pregnancy outcomes in systemic sclerosis and myositis
Latika Gupta, Sanjay Gandhi Postgraduate Institute of Medical Sciences, India
Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Asian RA Patients With MTX-IR from Phase III Study
Yoshiya Tanaka, University of Occupational And Environmental Health, Japan
Efficacy and Safety of Guselkumab, an anti-IL-23p19 mAb, in Biologic-naïve Patients with Active PsA Through Week-52 of a Phase-3 Study
Daniel Furtner, Janssen, A Division of Johnson & Johnson, Singapore
Oriental Wisdom on Risk and Causality
Dr Ashish Mathews, Christian Medical College, India
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Tsutomu Takeuchi, Keio University School of Medicine, Japan
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis
Steve Peterson, Janssen Global Services, United States of America
TBAPanel Q&APharmacokinetics, safety and tolerability of otilimab in Japanese patients with active moderate-to-severe rheumatoid arthritis despite treatment with methotrexate
Tatsuya Atsumi, Hokkaido University, Japan
Whether Modifiable Lifestyle and Environmental Factors Affect the Onset of Psoriatic Arthritis in Patients with Psoriasis?
Wenhui Xie, Peking University First Hospital, China
TBAUpdates on the SSc/myositis APLAR collaboration
Takahisa Gono, Nippon Medical School Graduate School of Medicine, Japan
Certolizumab Pegol in Patients with Rheumatoid Arthritis: Pooled Efficacy Analysis of Phase 3 Clinical Trials across Baseline Rheumatoid Factor Quartiles
Yoshiya Tanaka, University of Occupational and Environmental Health, Japan
Assessment of Nail Bed Thickness by Ultrasound in patients with Psoriatic arthritis and their correlation with Disease activity indices
Prajakta Dekate, Hyderabad Rheumatology Center, India
TBASustainability of Response to Upadacitinib Alone or In Combination Among Rheumatoid Arthritis Patients with Inadequate Response to Conventional Synthetic DMARDs
Peter Nash, Griffith University, Australia
Guselkumab for Active Psoriatic Arthritis: One-Year Results of a Phase-3, Randomized, Double-Blind, Placebo-Controlled Study of Biologic-Naïve or TNFα Inhibitor-Experienced Patients
James Wei, Chung Shan Medical University Hospital, Taiwan
Panel Q&AAmyopathic Dermatomyositis Associated ILD -the Asian experience – Experience from China
Ye Shuang, Shanghai Renji Hospital South Campus, China
TBAGuselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from DISCOVER-1 Psoriatic Arthritis Trial
James Wei, Chung Shan Medical University Hospital, Taiwan
Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis
Kunihiro Yamaoka, Kitasato University School of Medicine, Japan
Long term association of Streptococcus tonsillitis and subsequent risk of psoriasis: A population-based, big data, cohort analysis
Ming-Li Chen, Chung Shan Medical University, Taiwan
The Management of Rapidly Progressive Interstitial Lung Disease Associated with Clinically Amyopathic Dermatomyositis in Japan
Shinji Sato, Tokai University School of Medicine, Japan
Long-Term Safety and Efficacy of Upadacitinib in Japanese Patients with Rheumatoid Arthritis and Inadequate Response to csDMARDs: Results from SELECT-SUNRISE
Hideto Kameda, Toho University (Ohashi Medical Center), Japan
Efficacy and Safety of Upadacitinib Versus Placebo and Adalimumab in Patients with PsA and Inadequate Response to Non-Biologic DMARDs (SELECT-PsA-1)
Mitsumasa Kishimoto, Kyorin University School of Medicine, Japan
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 weeks from the SELECT-MONOTHERAPY Study
Yoshiya Tanaka, University of Occupational and Environmental Health, Japan
Efficacy and Safety of Upadacitinib in Patients with PsA and Inadequate Response to Biologic DMARDs (SELECT-PsA-2)
Shigeyoshi Tsuji, Kyorin University School of Medicine, Japan
Panel Q&AJoint Q&AEfficacy of Guselkumab on Axial-Involvement Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-24 Results from Two Phase-3 Studies
May Shawi, Janssen Global Services, United States of America
Joint Q&A
1615 – 1630Break
1630 – 1800
Industry symposium
Industry symposium
1800 – 1830Poster exhibition / viewing
Thursday 29 October
1515 – 1615SIG General AssemblyAYR Symposium: genetics in autoimmune diseasesAbstract session: SpA, AS-2Abstract session: Rheumatoid arthritis
Session information pendingGenetics in Autoimmune Diseases Made Easy
Yukinori Okada
Japan
Characteristics of peripheral blood lymphocyte subsets in patients with ankylosing spondylitis
Zheng Li, The Second Hospital of Shanxi Medical University, China
Predictors of serious infections in patients with rheumatoid arthritis receiving bDMARDs or tsDMARDs
Ekaterina Koltsova, Research Institute of The Organization of Health and Healthcare Management, Russia
Association of Obesity with Worse Disease Severity and Treatment Response in Ankylosing Spondylitis: Data from the Smart-phone SpondyloArthritis Management System
Lidong Hu, Chinese PLA General Hospital, China
Tofacitinib may have a direct analgesic effect. Data from the Moscow Unified Register of Arthritis (MUAR)
Evgeny Zhilyaev, Russian Medical Academy of Continuing Professional Education, Russia
TBASwitch from original “Mabtera” to Rituximab Biosimilar BCD-020 in Rheumatoid Arthritis Patients in Real-World Clinical Practice According to MUAR Data
Galina Lukina, Moscow Clinical Scientific Center Named After А.s.loginov, Russia
Pharmacogenetics in Autoimmune Diseases
Khai Pang Leong
Singapore
Randomized Controlled Trial of Oral Corticosteroids in Axial Spondyloarthritis : Modified COBRA regime (COBRA-AS)
Debashish Mishra, Pgimer, India
TBA
Secukinumab Improves Signs and Symptoms of Non-radiographic Axial Spondyloarthritis in Patients Naïve to TNF Inhibitor: Results from the PREVENT Study
Hideto Kameda, Toho University, Japan
DAS28 Remission and Low Disease Activity Among Rheumatoid Arthritis Patients in the United Arab Emirates
Sakina Asghar, American School of Dubai, United Arab Emirates
Treatment-Related Outcomes of Ankylosing Spondylitis Patients Initiating Biologic Therapy in Taiwan – A Population-Based Analysis
Chia-Fang Lee, Eli Lilly and Company, Taiwan
Attitudes towards medications in Rheumatoid arthritis patients attending a tertiary care clinic in Sri Lanka
Shalini Janagan, National Hospital of Sri Lanka, Sri Lanka
Joint Q&AJoint Q&APrevalence And Related Factors Of Depression In Rheumatoid Arthritis Patients
Thu Pham Hoai, Hanoi Medical University – Hanoi Medical University Hospital, Vietnam
1615 – 1630Break
1630 – 1800
Industry symposium
Industry symposium
1800 – 1830Poster exhibition / viewing